

Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021

<https://marketpublishers.com/r/P5C713B7B4E0EN.html>

Date: June 2021

Pages: 210

Price: US\$ 1,000.00 (Single User License)

ID: P5C713B7B4E0EN

Abstracts

With the COVID-19 having made a severe impact on various industries in the United States, it is challenging to predict precisely how the pharmaceutical and healthcare market will be performing in a short time. However, there is no doubt that the pharmaceutical and healthcare sector has been affected seriously. With the economic slowdown setting in due to the pandemic, the US pharmaceutical and healthcare industry is expected to decelerate in the short term.

The US pharmaceutical industry is a highly globalized industry dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. Over the past few decades, the industry has undergone dramatic structural changes, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.

Aruvian Research presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of United States in its research report Pharmaceutical and Healthcare Industry in the US – Forecast and Analysis 2021. The report covers the following data:

An in-depth coverage of the pharmaceutical and healthcare industry in the US by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.

We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for clinical trials in the US.

A SWOT analysis of the US pharmaceutical and healthcare industry.

A Porter's Five Forces Strategic Analysis of the US pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.

We take an up-close view of the regulatory framework governing the US pharmaceutical and healthcare industry.

Competition in the industry, along with an in-depth analysis of the major players like AstraZeneca, Eli Lilly, Glaxo Smith Kline, and many others are included.

A detailed forecast of the US pharmaceutical and healthcare industry by segments completes this comprehensive analysis.

Contents

A. EXECUTIVE SUMMARY

B. INDUSTRY DEFINITION

C. PHARMACEUTICAL & HEALTHCARE INDUSTRY IN THE US

- C.1 Impact of COVID-19 on the Industry
- C.2 Pharmaceutical Sector Analysis
- C.3 Healthcare Sector Analysis
- C.4 Market for Prescription Drugs
- C.5 Market for Patented Drugs
- C.6 Market for OTC Medicines
- C.7 Market for Generic Drugs
- C.8 Clinical Trials in the US

D. US PHARMACEUTICAL & HEALTHCARE INDUSTRY: SWOT ANALYSIS

- D.1 Strengths to Build Upon
- D.2 Weaknesses to Overcome
- D.3 Opportunities to Exploit
- D.4 Threats to Overcome

E. US PHARMACEUTICAL INDUSTRY: PORTER'S FIVE FORCES STRATEGY ANALYSIS

- E.1 Bargaining Power of Buyers
- E.2 Bargaining Power of Suppliers
- E.3 Competitive Rivalry in the Industry
- E.4 Threat of New Entrants
- E.5 Threat of Substitutes

F. CHRONIC MEDICAL CONDITIONS IN THE US

- F.1 Overview
- F.2 Alzheimer's Disease
- F.3 Arthritis
- F.4 Cancer

F.5 Cardiovascular Disease

F.6 Diabetes

F.7 Obesity

G. REGULATORY FRAMEWORK OF THE INDUSTRY

G.1 Overview

G.2 Regulations for New Drugs

G.3 The American Health Care Act

G.4 Other Regulations

G.4.1 Prescription Drug User Fee Act

G.4.2 Regulations governing Generic Drugs

G.4.3 Bolar Amendment

G.4.4 Regulations governing Biosimilars

G.4.5 Regulations governing OTC Medicines

G.4.6 Tax Reform Bill

G.4.7 Pricing and Reimbursement Regime

G.4.8 Proposition 61 - The California Drug Price Relief Act

G.4.9 Senate Bill No.

G.4.10 Regulations governing Promotion of Pharmaceuticals

G.4.11 What does the Payer Landscape look like?

G.5 Challenges with Intellectual Property Rights

H. IMPORT/EXPORT OF PHARMACEUTICALS

I. COMPETITION IN THE INDUSTRY

I.1 Competitive Landscape

I.2 Impact of COVID-19 on Competition

I.3 Impacts on Competition

I.4 Competition in the Generic Drugs Sector

I.5 Competition in the US Pharmacy Sector

I.6 Competition in the US Drug Distribution Market

J. FORECAST: PHARMACEUTICAL & HEALTHCARE INDUSTRY IN THE US

J.1 Outlook of the US Pharmaceutical Industry

J.2 Outlook of the US Healthcare Industry

J.3 Outlook for Prescription Drugs Sector

J.4 Outlook for Patented Drugs Market

J.5 Outlook for OTC Medicine Market

J.6 Outlook for the Generic Drugs Market

K. PHARMACEUTICAL & HEALTHCARE INDUSTRY: MAJOR PLAYERS

K.1 AbbVie

K.1.1 Corporate Analysis

K.1.2 Business Segment Analysis

K.1.3 Financial Analysis

K.1.4 SWOT Analysis

K.2 Amgen

K.2.1 Corporate Analysis

K.2.2 Business Segment Analysis

K.2.3 Financial Analysis

K.2.4 SWOT Analysis

K.3 Apotex

K.3.1 Corporate Analysis

K.3.2 Business Segment Analysis

K.3.3 Financial Analysis

K.3.4 SWOT Analysis

K.4 AstraZeneca

K.4.1 Corporate Analysis

K.4.2 Business Segment Analysis

K.4.3 Financial Analysis

K.4.4 SWOT Analysis

K.5 Bristol Myers Squibb

K.5.1 Corporate Analysis

K.5.2 Business Segment Analysis

K.5.3 Financial Analysis

K.5.4 SWOT Analysis

K.6 Eli Lilly and Company

K.6.1 Corporate Analysis

K.6.2 Business Segment Analysis

K.6.3 Financial Analysis

K.6.4 SWOT Analysis

K.7 Gilead Sciences

K.7.1 Corporate Analysis

K.7.2 Business Segment Analysis

K.7.3 Financial Analysis

K.7.4 SWOT Analysis

K.8 GlaxoSmithKline

K.8.1 Corporate Analysis

K.8.2 Business Segment Analysis

K.8.3 Financial Analysis

K.8.4 SWOT Analysis

K.9 Johnson & Johnson

K.9.1 Corporate Analysis

K.9.2 Business Segment Analysis

K.9.3 Financial Analysis

K.9.4 SWOT Analysis

K.10 Merck & Co.

K.10.1 Corporate Analysis

K.10.2 Business Segment Analysis

K.10.3 Financial Analysis

K.10.4 SWOT Analysis

K.11 Novartis

K.11.1 Corporate Analysis

K.11.2 Business Segment Analysis

K.11.3 Financial Analysis

K.11.4 SWOT Analysis

K.12 Pfizer

K.12.1 Corporate Analysis

K.12.2 Business Segment Analysis

K.12.3 Financial Analysis

K.12.4 SWOT Analysis

K.13 Sanofi SA

K.13.1 Corporate Analysis

K.13.2 Business Segment Analysis

K.13.3 Financial Analysis

K.13.4 SWOT Analysis

K.14 Teva Pharmaceutical Industries Ltd.

K.14.1 Corporate Analysis

K.14.2 Business Segment Analysis

K.14.3 Financial Analysis

K.14.4 SWOT Analysis

L. GLOSSARY OF TERMS

M. RESEARCH METHODOLOGY

N. DISCLAIMER

List Of Figures

LIST OF FIGURES

- Figure 1: Growth of the Pharmaceutical Sales in the US, 2016-2030
- Figure 2: Clinical Trial Registrations in the US, 2016-2019
- Figure 3: Porter's Five Forces Analysis of the US Pharmaceutical Industry
- Figure 4: Bargaining Power of Buyers in the US Pharmaceutical Industry
- Figure 5: Bargaining Power of Suppliers in the US Pharmaceutical Industry
- Figure 6: Competitive Rivalry in the US Pharmaceutical Industry
- Figure 7: Threat of New Entrants to the US Pharmaceutical Industry
- Figure 8: Threat of Substitutes to the US Pharmaceutical Industry
- Figure 9: Import-Export of Pharmaceuticals in the US (in USD Million), 2016-2025
- Figure 10: Expenditure on Healthcare in the US, 2016-2030
- Figure 11: Forecast of the Prescription Drug Market in the US, 2016-2030
- Figure 12: Forecast of the Patented Drugs Sector in the US, 2016-2030
- Figure 13: Forecast of the OTC Medicine Market, 2016-2030
- Figure 14: Forecast of the Generic Drug Market in the US, 2017-2025

List Of Tables

LIST OF TABLES

Table 1: Growth of the Pharmaceutical Sales in the US, 2016-2030

Table 2: Healthcare Resources in the US, 2015-2020

Table 3: Inpatient/Outpatient Statistics in the US, 2015-2020

Table 4: Major Features of the Affordable Care Act

Table 5: Import-Export of Pharmaceuticals in the US (in USD Million), 2016-2025

Table 6: Market Share of Leading Players in the US Pharmaceutical Industry (%), 2020

Table 8: Statistics of the US Pharmaceutical & Healthcare Industry in the US, 2019-2025

Table 9: Expenditure on Healthcare in the US, 2016-2030

Table 10: Government Expenditure on Healthcare in the US, 2017-2025

Table 11: Healthcare Expenditure by Private Sector on Healthcare in the US, 2017-2025

Table 12: Forecast of the Prescription Drug Market in the US, 2016-2030

Table 13: Forecast of the Patented Drugs Sector in the US, 2016-2030

Table 14: Forecast of the OTC Medicine Market, 2016-2030

Table 15: Forecast of the Generic Drug Market in the US, 2017-2025

I would like to order

Product name: Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021

Product link: <https://marketpublishers.com/r/P5C713B7B4E0EN.html>

Price: US\$ 1,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P5C713B7B4E0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970